粘菌素甲烷磺酸钠结构式
|
常用名 | 粘菌素甲烷磺酸钠 | 英文名 | Colistin methanesulfonate sodium salt |
---|---|---|---|---|
CAS号 | 8068-28-8 | 分子量 | 1759.898 | |
密度 | N/A | 沸点 | N/A | |
分子式 | C58H115N16Na5O28S5 | 熔点 | N/A | |
MSDS | 美版 | 闪点 | N/A |
粘菌素甲烷磺酸钠用途Colistin methanesulfonate sodium salt对P. aeruginosa 敏感菌类的MIC 值为 4-16 mg/L. |
中文名 | 粘杆菌素甲基磺酸钠 |
---|---|
英文名 | colistin methanesulfonate sodium salt |
中文别名 | 粘杆菌素甲基磺酸钠 | 粘菌素甲烷磺酸钠 | 多粘菌素甲磺酸钠 | 多黏菌素E甲磺酸钠 |
英文别名 | 更多 |
描述 | Colistin methanesulfonate sodium salt对P. aeruginosa 敏感菌类的MIC 值为 4-16 mg/L. |
---|---|
相关类别 | |
体外研究 | 在相同的MIC倍数下,甲基磺酸粘杆菌素的杀菌能力比粘菌素低。粘菌素和甲磺酸粘菌素都是粘菌素A和B(1)两种成分盐的不均匀混合物,它们在体外可能有不同的活性[1]。 |
参考文献 |
分子式 | C58H115N16Na5O28S5 |
---|---|
分子量 | 1759.898 |
精确质量 | 1758.615845 |
外观性状 | white to faintly beige |
储存条件 | 2-8℃ |
水溶解性 | H2O: soluble10mg/mL |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:18 3.氢键受体数量:33 4.可旋转化学键数量:39 5.互变异构体数量:1001 6.拓扑分子极性表面积749 7.重原子数量:112 8.表面电荷:0 9.复杂度:3430 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:13 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:6 |
更多 | 1. 性状:未确定 2. 密度(g/mL 25ºC):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC常压):未确定 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,5.2kPa):未确定 7. 折射率(n20/D):未确定 8. 闪点(ºC,):未确定 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(kPa,25ºC):未确定 12. 饱和蒸气压(kPa,60ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值(25℃):未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性(mg/mL) :未确定 |
个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
危险品运输编码 | 3249 |
WGK德国 | 2 |
RTECS号 | GH1650000 |
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
J. Chromatogr. A. 1369 , 52-63, (2014) Colistin is a last resort's antibacterial treatment in critically ill patients with multi-drug resistant Gram-negative infections. As appropriate colistin exposure is the key for maximizing efficacy w... |
|
Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.
PLoS ONE 10 , e0142097, (2015) Exacerbations associated with chronic lung infection with Pseudomonas aeruginosa are a major contributor to morbidity, mortality and premature death in cystic fibrosis. Such exacerbations are treated ... |
|
In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Antimicrob. Agents Chemother. 45 , 781-785, (2001) The in vitro pharmacodynamic properties of colistin and colistin methanesulfonate were investigated by studying the MICs, time-kill kinetics, and postantibiotic effect (PAE) against mucoid and nonmuco... |
Colistrimethate sodium |
EINECS 232-516-9 |
MFCD00130824 |
Colimycin M |
Colistimethate sodium |
Sodium colistimethate |
Colistin sodium methanesulfonate |
Colistimethate |
Sodium methanesulfonate - N-[(2S)-4-amino-1-{[(2S,3R)-1-{[(2S)-4-amino-1-oxo-1-({(6S,9R,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-12,15-diisobutyl-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl}amino)-2-butanyl]amino}-3-hydroxy-1-oxo-2-butanyl]amino}-1-oxo-2-butanyl]-6-methyloctanamide (5:5:1) |